AlphaCore Capital LLC Purchases 6,206 Shares of AstraZeneca PLC $AZN

AlphaCore Capital LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 77.3% during the third quarter, HoldingsChannel.com reports. The fund owned 14,230 shares of the company’s stock after acquiring an additional 6,206 shares during the quarter. AlphaCore Capital LLC’s holdings in AstraZeneca were worth $1,092,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. NewSquare Capital LLC grew its stake in shares of AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. Rakuten Investment Management Inc. bought a new position in shares of AstraZeneca in the 3rd quarter valued at about $31,000. FSA Wealth Management LLC lifted its holdings in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after acquiring an additional 376 shares during the last quarter. VSM Wealth Advisory LLC purchased a new position in AstraZeneca in the second quarter worth about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after acquiring an additional 275 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 2.3%

NASDAQ:AZN opened at $208.72 on Friday. The company has a market cap of $323.71 billion, a price-to-earnings ratio of 69.34, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a twelve month low of $122.48 and a twelve month high of $212.71. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a fifty day simple moving average of $135.91 and a 200-day simple moving average of $102.01.

AstraZeneca Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is 74.83%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Morgan Stanley restated an “overweight” rating and issued a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Wall Street Zen lowered shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.